Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Manufacturer Doesn’t Expect Zika Blood-Screening Test Shortage

Executive Summary

US FDA has asked Miami-area blood banks to close until they can screen all blood supplies for the Zika virus in the wake of the first known cases transmitted by mosquitos within the US. A manufacturer of the only test currently available for blood-bank use does not expect shortages, despite the increased demand.

You may also be interested in...



Hologic/Grifols, Roche Molecular Zika Tests Tapped For Blood-Screening Ramp-Up

A blood-screening test made by Hologic in collaboration with Grifols, and another made by Roche Molecular Diagnostics, are being used in a gradual ramp-up of Zika virus screening at blood donation centers across the US under a new FDA program.

FDA Clears Another Zika Assay, Luminex's xMap

The xMap Multiflex Zika RNA Assay is a molecular diagnostic that is designed to detect the Zika virus in human serum, urine or plasma.

House-Senate Conferees Fight Over Zika Funds As FDA Approves More Assays

Emergency funding to battle the summer's mosquito-borne Zika threat is trapped in a military/VA spending bill. Conferees must find a compromise between the House's $622m bid and the Senate's $1.1b offer in the thin stretch of time when both chambers will be session before they adjourn on July 15. In the interim, FDA has authorized more Zika tests.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT103661

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel